Table 4.
Univariate regression analysis of complications seen in malignant SVT in comparison with SVT associated with non-GI malignancies
| Complication | Non-GI malignancy, n (%) | Hepatic cancer, n (%) | Unadjusted odds ratio | Pancreatic cancer, n (%) | Unadjusted odds ratio | Colon cancer, n (%) | Unadjusted odds ratio |
|---|---|---|---|---|---|---|---|
| Hepatic encephalopathy | 700 (2.2) | 77 (4.7) | 2.22 (1.74–2.82) | 20 (2.3) | 0.98 (0.62–1.53) | 10 (4) | 0.91 (0.48–1.71) |
| Mesenteric ischemia | 1,241 (3.9) | 34 (2.2) | 0.53 (0.37–0.74) | 34 (3.7) | 0.93 (0.66–1.32) | 25 (5) | 1.3 (0.86–1.95) |
| Intracranial hemorrhage | 127 (0.04) | 5 (0.3) | 0.77 (0.31–1.9) | 5 (0.4) | 0.57 (0.16–1.99) | 0 (0) | 3.4 (0.18–61.6) |
| Ascites | 3,913 (12.3) | 512 (31.7) | 3.32 (2.97–3.7) | 240 (26) | 2.51 (2.16–2.92) | 64 (12.8) | 1.05 (0.80–1.37) |
| Transfusion of blood products | 1,145 (3.6) | 76 (4.7) | 1.32 (1.04–1.68) | 6 (0.7) | 0.17 (0.07–0.39) | 18 (3.7) | 1.11 (0.067–1.76) |
| Prolonged ventilation | 604 (1.9) | 40 (2.5) | 1.31 (0.95–1.81) | 40 (4.4) | 2.33 (1.68–3.23) | 8 (1.6) | 0.84 (0.41–1.7) |
| Variceal bleeding | 3,573 (10.4) | 262 (16.3) | 1.67 (1.2–2.34) | 37 (4) | 0.35 (0.16–0.75) | 27 (5.5) | 0.5 (0.23–1.09) |
SVT, splanchnic vein thrombosis.